SynthesisBMC gastroenterology2026
TRPV6, a new entrant as a susceptibility gene in chronic pancreatitis: evidence from a systematic review and meta-analysis.
Synthesis in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPancreatitis, a debilitating disease, is orchestrated by many etiological factors. Besides the known causal genes, including PRSS1, SPINK1, CPA1, CFTR, etc., of late, TRPV6 has emerged as a new candidate in the list. We aimed to investigate the role of TRPV6 and its genetic variations in the etiopathology of pancreatitis.
methodsWe conducted a systematic review and meta-analysis of published articles on TRPV6 and pancreatitis in the databases including PubMed, Google Scholar, Medline, and Web of Science. Pooled odds ratios (pORs) and 95% confidence intervals (CIs) were determined to evaluate the associations of common TRPV6 variants with the risk of pancreatitis. Bioinformatic analysis was also performed to evaluate the pathogenicity of reported variants.
resultsUnlike controls, the pathogenic TRPV6 variations were overrepresented in pancreatitis cases from diverse ethnicities. We observed a cumulative inverse association of p.Ala18Ser (pooled OR = 0.51; 95%CI:0.4–0.61; p < 0.001) with the pancreatitis risk. A high risk of developing pancreatitis was found in subjects harbouring the variant genotype of p.Ile223Thr (pOR = 1.75; 95%CI:1.03–2.47;p < 0.001). A dysregulated Ca2+ ion homeostasis is central in modulating the pancreatitis risk among subjects harbouring TRPV6 variants.
conclusionEvidence suggests that TRPV6 is a novel gene to modulate the pancreatitis risk, and the defective variants can be inherited in families. This discovery offers a novel target for therapeutic intervention as well. The findings of the study support the inclusion of TRPV6 in genetic testing panels for pancreatitis, while recognizing that further large-scale studies will help refine its clinical utility.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.